Join Growin Stock Community!

Galectin therapeutics inc.GALT.US Overview

US StockHealthcare
(No presentation for GALT)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

GALT AI Insights

GALT Overall Performance

GALT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

GALT Recent Performance

-4.59%

Galectin therapeutics inc.

-3.61%

Avg of Sector

-2.16%

S&P500

GALT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

GALT Key Information

GALT Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

GALT Profile

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Price of GALT

GALT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

GALT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.58
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
207.70
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.58
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
207.70
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is GALT's latest earnings report released?

    The most recent financial report for Galectin therapeutics inc. (GALT) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating GALT's short-term business performance and financial health. For the latest updates on GALT's earnings releases, visit this page regularly.

  • How much cash does GALT have?

    At the end of the period, Galectin therapeutics inc. (GALT) held Total Cash and Cash Equivalents of 11.53M, accounting for 0.9 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is GALT's EPS continuing to grow?

    According to the past four quarterly reports, Galectin therapeutics inc. (GALT)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.13. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of GALT?

    Galectin therapeutics inc. (GALT)'s Free Cash Flow (FCF) for the period is -3.54M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 58.51% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of GALT?

    The latest valuation data shows Galectin therapeutics inc. (GALT) has a Price-To-Earnings (PE) ratio of -9.49 and a Price/Earnings-To-Growth (PEG) ratio of -1. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.